EXPOSURE-RESPONSE CHARACTERISTICS AND PREDICTORS OF EFFICACY IN MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS PATIENTS RECEIVING TOFACITINIB.

被引：0
|
作者：
Hutmacher, M. M. [1 ]
Papp, K. A. [2 ]
Lebwohl, M. [3 ]
Ito, K. [4 ]
Tan, H. [4 ]
Wolk, R. [4 ]
Mebus, C. [4 ]
Rottinghaus, S. [4 ]
Valdez, H. [5 ]
Krishnaswami, S. [4 ]
Gupta, P. [4 ]
机构：
[1] Ann Arbor Pharmacometr Grp A2PG, Ann Arbor, MI USA
[2] Prob Med Res & K Papp Clin Res Inc, Waterloo, ON, Canada
[3] Icahn Sch Med Mt Sinai, Kimberly & Eric J Waldman Dept Dermatol, New York, NY 10029 USA
[4] Pfizer Inc, Groton, CT 06340 USA
[5] Pfizer Inc, New York, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-082
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [11] Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics
    Kim, Tae-Rim
    Won, Yumi
    Kim, Yeona
    Won, Sang-Hyeon
    Bae, Kyung-Nam
    Lee, Jungsoo
    Shin, Kihyuk
    Kim, Hoonsoo
    Ko, Hyunchang
    Kim, Moon-Bum
    Kim, Byungsoo
    EUROPEAN JOURNAL OF DERMATOLOGY, 2023, 33 (05) : 518 - 523
  • [12] Exposure-response relationships for efficacy and safety of risankizumab in patients with moderate to severe plaque psoriasis: Integrated analyses of phase 2 and 3 clinical trials
    Khatri, Amit
    Suleiman, Ahmed A.
    Polepally, Akshanth R.
    Othman, Ahmed A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB209 - AB209
  • [13] The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    Menter, A
    Cather, JC
    Baker, D
    Farber, HF
    Lebwohl, M
    Darif, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (01) : 61 - 63
  • [14] Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis
    Chigutsa, Emmanuel
    de Mendizabal, Nieves Velez
    Chua, Laiyi
    Heathman, Michael
    Friedrich, Stuart
    Jackson, Kimberley
    Reich, Kristian
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (11): : 1489 - 1500
  • [15] Safety and efficacy of efalizumab therapy for elderly patients with moderate to severe chronic plaque psoriasis
    Gottlieb, A
    Lizzul, P
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P194 - P194
  • [16] Population Exposure-Response Model to Support Dosing Evaluation of Ixekizumab in Patients With Chronic Plaque Psoriasis
    Tham, Lai-San
    Tang, Cheng-Cai
    Choi, Siak-Leng
    Satterwhite, Julie H.
    Cameron, Gregory S.
    Banerjee, Subhashis
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (10): : 1117 - 1124
  • [17] Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis
    Leonardi, C
    Goffe, B
    Sobell, J
    Caro, I
    Wang, X
    Papp, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A58 - A58
  • [18] Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis
    Papp, KA
    Miller, B
    Gordon, KB
    Caro, I
    Kwon, P
    Compton, PG
    Leonardi, CL
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (04) : S164 - S170
  • [19] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
    Bissonnette, R.
    Iversen, L.
    Sofen, H.
    Griffiths, C. E. M.
    Foley, P.
    Romiti, R.
    Bachinsky, M.
    Rottinghaus, S. T.
    Tan, H.
    Proulx, J.
    Valdez, H.
    Gupta, P.
    Mallbris, L.
    Wolk, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) : 1395 - 1406
  • [20] Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
    Di Lernia, V.
    Bardazzi, F.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 533 - 539
12345